75岁及以上上皮性卵巢癌患者单纯化疗——是否仍需间期减瘤手术?
基于美国国家癌症数据库2004至2014年1661例75岁及以上卵巢癌患者数据,比较单纯化疗与新辅助化疗联合间期减瘤手术的总生存。接受新辅助化疗联合间期减瘤手术者5年总生存为25%,单纯化疗组仅7%(P<.001);多变量分析中间期减瘤手术为生存改善的独立预测因素(HR 0.44,95%CI 0.36-0.54,P<.001)。
要点
- 75岁及以上卵巢癌患者接受新辅助化疗联合间期减瘤手术者5年总生存25%,单纯化疗组仅7%(P<.001)。
- 多变量分析中,新辅助化疗联合间期减瘤手术是生存改善的独立预测因素(HR 0.44,95%CI 0.36-0.54,P<.001)。
- 年龄80-84岁、III-IV期疾病和透明细胞组织学与更差结局相关(HR分别为1.35、2.06、2.17)。
核心结论
- 75岁及以上卵巢癌患者总体预后差,接受新辅助化疗后间期减瘤手术与较单纯化疗更高的总生存相关。
研究设计与样本
- 数据提取自美国国家癌症数据库2004至2014年,共1661例75岁及以上卵巢癌患者,中位年龄79岁。
- 采用Kaplan-Meier法和Cox比例风险模型进行统计分析。
主要发现
- 1661例患者中大多数为白人(88%)、III-IV期疾病(95%),51%为浆液性组织学。
- 未接受初次手术的患者中,58%接受单纯化疗,其余接受新辅助化疗联合间期减瘤手术。
- 新辅助化疗联合间期减瘤手术的使用率从2004-2007年的28%上升至2012-2014年的50%(P<.001)。
- 与接受新辅助化疗联合间期减瘤手术者相比,单纯化疗患者年龄更大(80岁 vs 78岁;P<.001)且晚期疾病比例更高(98% vs 91%;P<.001)。
- 全研究组5年总生存为14%;新辅助化疗联合间期减瘤手术组总生存为25%,单纯化疗组仅7%(P<.001)。
关键数值与推荐
- 多变量分析中,新辅助化疗联合间期减瘤手术是生存改善的独立预测因素(HR 0.44,95%CI 0.36-0.54,P<.001)。
- 年龄80-84岁与更差结局相关(HR 1.35,95%CI 1.12-1.63,P=.002)。
- III-IV期疾病与更差结局相关(HR 2.06,95%CI 1.37-3.09,P=.001)。
- 透明细胞组织学与更差结局相关(HR 2.17,95%CI 1.10-4.28,P=.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients ≥75 years old with ovarian cancer experience high perioperative morbidity, but recruitment into prospective trials to assess the role of surgery continues to be challenging. OBJECTIVE: To compare overall survival for patients ≥75 years old with ovarian cancer after chemotherapy alone vs neoadjuvant chemotherapy with interval cytoreductive surgery. STUDY DESIGN: Data were extracted from the National Cancer Data Base from 2004 to 2014. Kaplan-Meier and Cox proportional hazards models were used for statistical analyses. RESULTS: Of 1661 patients (median age: 79 years), most were white (88%) and had stage III-IV disease (95%), and 51% had serous histology. Of those who did not receive primary surgery, 58% had chemotherapy alone and the remainder had neoadjuvant chemotherapy with interval cytoreductive surgery. The use of neoadjuvant chemotherapy with interval cytoreductive surgery increased from 28% to 50% in years 2004-2007 to 2012-2014 (P<.001). Compared with neoadjuvant chemotherapy with interval cytoreductive surgery, chemotherapy-only patients were older (80 vs 78 years; P<.001) and had more advanced stage disease (98% vs 91%; P<.001). The 5-year overall survival of the entire study group was 14%; those who underwent neoadjuvant chemotherapy with interval cytoreductive surgery had overall survival of 25% compared with only 7% in chemotherapy alone group (P<.001). In multivariable analysis, neoadjuvant chemotherapy with interval cytoreductive surgery (hazard ratio, 0.44; 95% confidence interval, 0.36-0.54; P<.001) was an independent predictor for improved survival. Older (80-84 years) age (hazard ratio, 1.35; 95% confidence interval, 1.12-1.63; P=.002), advanced (stage III-IV) disease (hazard ratio; 2.06, 95% confidence interval, 1.37-3.09; P=.001), and clear cell histology (hazard ratio; 2.17, 95% confidence interval, 1.10-4.28; P=.03) portended for worse outcome. CONCLUSION: Patients ≥75 years with ovarian cancer old have an overall poor prognosis. Receiving neoadjuvant chemotherapy followed by interval cytoreductive surgery is associated with greater overall survival compared to chemotherapy alone.
引用
- Klein DA, Mann AK, Freeman AH, et al. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed? Am J Obstet Gynecol. 2019. PMID: 31421122. doi:10.1016/j.ajog.2019.07.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。